Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

Imagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...

The fully funded study is expected to evaluate TNF-a levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. TNFA is ...

The annual meeting of the American Society of Hematology was held from Dec. 7 to 10 in San Diego and attracted participants ...

For more than 15 years, researchers at the Icahn School of Medicine at Mount Sinai have worked tirelessly to find a solution ...

Nicoya PuraTea is a nutritional support intricately fabricated to support healthy weight loss. It uses selected ingred ...

And if you have any idea what that means, it might be too late for you. Fortnite is no stranger to collaborations, from ...

William Blair analyst Sami Corwin maintained a Buy rating on Neurogene (NGNE – Research Report) yesterday. The company’s shares opened today at ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and ...